Pictet Asset Management
FOLD

Pictet Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Pictet Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Sell
893,901
-1,100,954
-55% -$15.8M 0.01% 588
2025
Q4 		$28.4M Sell
1,994,855
-4,793,309
-71% -$47.1M 0.03% 440
2025
Q3 		$53.6M Buy
6,788,164
+2,880,595
+74% +$20.5M 0.05% 312
2025
Q2 		$22.8M Buy
3,907,569
+2,279,356
+140% +$14.7M 0.02% 479
2025
Q1 		$13.7M Buy
1,628,213
+110,577
+7% +$1.02M 0.02% 580
2024
Q4 		$14.3M Sell
1,517,636
-110,241
-7% -$1.15M 0.02% 578
2024
Q3 		$17.4M Sell
1,627,877
-2,588,334
-61% -$28.2M 0.02% 523
2024
Q2 		$41.8M Sell
4,216,211
-2,551,162
-38% -$26.2M 0.05% 315
2024
Q1 		$79.9M Sell
6,767,373
-227,224
-3% -$2.91M 0.09% 234
2023
Q4 		$99.3M Sell
6,994,597
-1,402,914
-17% -$15.9M 0.11% 204
2023
Q3 		$102M Buy
+8,397,511
New +$108M 0.13% 188

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Pictet Asset Management's FOLD Position: Q1 2026 in Review

Pictet Asset Management reduced its Amicus Therapeutics (FOLD) stake by 55% in Q1 2026, selling an estimated $15.8M and leaving 893,901 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #588.

Pictet Asset Management first reported a position in FOLD in Q3 2023 and has held it in 11 quarters since. The position peaked at $102M in Q3 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Pictet Asset Management held 893,901 shares of Amicus Therapeutics worth $12.9M as of Q1 2026.
  • Pictet Asset Management sold 1,100,954 Amicus Therapeutics shares in Q1 2026, an estimated $15.8M.
  • Amicus Therapeutics made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #588 holding.
  • Pictet Asset Management first reported a position in Amicus Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Amicus Therapeutics position peaked at $102M in Q3 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.